Malaysiakini
NEWS

New Brazil data shows only 50.4% efficacy for China's CoronaVac vaccine

Reuters

Published
Modified 13 Jan 2021, 2:29 am

A coronavirus vaccine developed by China's Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last week.

The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world's second-deadliest Covid-19 outbreak.

All Access Plan
starting from

~RM12

per month
Subscribe Now
You can cancel anytime.
Get unlimited access to our articles on web and apps
Add comments to our articles
Bookmark articles to read later
We accept
Student or Senior Citizen? Get a special rateGroup / Institutional / Corporate Plans
Already Subscribed?
Sign In

Share